AB0122 THE NORA PROJECT - PREDICTION OF THERAPY RESPONSE IN RHEUMATOID ARTHRITIS
Background: Personalized medicine in Rheumatoid arthritis (RA) especially regarding therapy response is still in early stages. The Nordic RA (NORA) project is aiming to improve the prediction of therapy outcome by combining established serologic marker with new markers, genetic information and patie...
Published in: | Annals of the Rheumatic Diseases |
---|---|
Main Authors: | , , , , , , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
BMJ
2021
|
Subjects: | |
Online Access: | http://dx.doi.org/10.1136/annrheumdis-2021-eular.2024 https://syndication.highwire.org/content/doi/10.1136/annrheumdis-2021-eular.2024 |
id |
crjcrbmj:10.1136/annrheumdis-2021-eular.2024 |
---|---|
record_format |
openpolar |
spelling |
crjcrbmj:10.1136/annrheumdis-2021-eular.2024 2024-02-11T10:01:16+01:00 AB0122 THE NORA PROJECT - PREDICTION OF THERAPY RESPONSE IN RHEUMATOID ARTHRITIS Mathsson-Alm, L. Gehring, I. Poorafshar, M. Rönnelid, J. Askling, J. Haavardsholm, E. Berner Hammer, H. 2021 http://dx.doi.org/10.1136/annrheumdis-2021-eular.2024 https://syndication.highwire.org/content/doi/10.1136/annrheumdis-2021-eular.2024 en eng BMJ Annals of the Rheumatic Diseases volume 80, issue Suppl 1, page 1090.2-1090 ISSN 0003-4967 1468-2060 General Biochemistry, Genetics and Molecular Biology Immunology Immunology and Allergy Rheumatology journal-article 2021 crjcrbmj https://doi.org/10.1136/annrheumdis-2021-eular.2024 2024-01-26T10:14:52Z Background: Personalized medicine in Rheumatoid arthritis (RA) especially regarding therapy response is still in early stages. The Nordic RA (NORA) project is aiming to improve the prediction of therapy outcome by combining established serologic marker with new markers, genetic information and patient-derived data. Objectives: As an initial step in the project the aim was to select clinically characterized patient cohorts and evaluate if changes or patterns in serological markers could predict therapy response and/or disease progress. Methods: The ARCTIC ( A iming for R emission in rheumatoid arthritis: a randomised trial examining the benefit of ultrasound in a C linical TI ght C ontrol regimen) study [1] was designed to compare two tight control treatment strategies for early Rheumatoid arthritis and was used as a first cohort. Plasma samples (n=1622) from 224 RA patients from the ARCTIC study were included and taken at baseline and 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 months from trial start, and analyzed for the presence of EliA TM RF (IgM, IgA, IgG), anti-CCP (IgG, IgA) and anti-RA33 (IgM, IgA, IgG) autoantibodies, as well as Calprotectin using the EliA instrument platform (Phadia AB, Uppsala, Sweden). In addition, a custom-made multiplex chip (Thermo Fisher Scientific, Sweden) [2] was used for measurement of anti-IgG antibodies against RA-specific antigens (citrullinated, acetylated and carbamylated), and established CTD-markers (Connective Tissue Disease), e.g. Ro52/60 and dsDNA. The citrullinated peptides on the multiplex chip were both multiple as well as single citrullinated at different positions within the peptide sequence. Additionally, we included an ELISA to measure antibodies against native human collagen II [3]. Results: The different single assays in the baseline samples varied between 7 – 80% positive test results, e.g. anti-CCP IgG 80%. For some patients we could see changes in levels for anti-CCP, RF and anti-RA33 in the follow up samples, which varied from negative to more than 3-10xULN ... Article in Journal/Newspaper Arctic The BMJ Arctic Elia ENVELOPE(20.166,20.166,70.157,70.157) Annals of the Rheumatic Diseases 80 Suppl 1 1090.2 1090 |
institution |
Open Polar |
collection |
The BMJ |
op_collection_id |
crjcrbmj |
language |
English |
topic |
General Biochemistry, Genetics and Molecular Biology Immunology Immunology and Allergy Rheumatology |
spellingShingle |
General Biochemistry, Genetics and Molecular Biology Immunology Immunology and Allergy Rheumatology Mathsson-Alm, L. Gehring, I. Poorafshar, M. Rönnelid, J. Askling, J. Haavardsholm, E. Berner Hammer, H. AB0122 THE NORA PROJECT - PREDICTION OF THERAPY RESPONSE IN RHEUMATOID ARTHRITIS |
topic_facet |
General Biochemistry, Genetics and Molecular Biology Immunology Immunology and Allergy Rheumatology |
description |
Background: Personalized medicine in Rheumatoid arthritis (RA) especially regarding therapy response is still in early stages. The Nordic RA (NORA) project is aiming to improve the prediction of therapy outcome by combining established serologic marker with new markers, genetic information and patient-derived data. Objectives: As an initial step in the project the aim was to select clinically characterized patient cohorts and evaluate if changes or patterns in serological markers could predict therapy response and/or disease progress. Methods: The ARCTIC ( A iming for R emission in rheumatoid arthritis: a randomised trial examining the benefit of ultrasound in a C linical TI ght C ontrol regimen) study [1] was designed to compare two tight control treatment strategies for early Rheumatoid arthritis and was used as a first cohort. Plasma samples (n=1622) from 224 RA patients from the ARCTIC study were included and taken at baseline and 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 months from trial start, and analyzed for the presence of EliA TM RF (IgM, IgA, IgG), anti-CCP (IgG, IgA) and anti-RA33 (IgM, IgA, IgG) autoantibodies, as well as Calprotectin using the EliA instrument platform (Phadia AB, Uppsala, Sweden). In addition, a custom-made multiplex chip (Thermo Fisher Scientific, Sweden) [2] was used for measurement of anti-IgG antibodies against RA-specific antigens (citrullinated, acetylated and carbamylated), and established CTD-markers (Connective Tissue Disease), e.g. Ro52/60 and dsDNA. The citrullinated peptides on the multiplex chip were both multiple as well as single citrullinated at different positions within the peptide sequence. Additionally, we included an ELISA to measure antibodies against native human collagen II [3]. Results: The different single assays in the baseline samples varied between 7 – 80% positive test results, e.g. anti-CCP IgG 80%. For some patients we could see changes in levels for anti-CCP, RF and anti-RA33 in the follow up samples, which varied from negative to more than 3-10xULN ... |
format |
Article in Journal/Newspaper |
author |
Mathsson-Alm, L. Gehring, I. Poorafshar, M. Rönnelid, J. Askling, J. Haavardsholm, E. Berner Hammer, H. |
author_facet |
Mathsson-Alm, L. Gehring, I. Poorafshar, M. Rönnelid, J. Askling, J. Haavardsholm, E. Berner Hammer, H. |
author_sort |
Mathsson-Alm, L. |
title |
AB0122 THE NORA PROJECT - PREDICTION OF THERAPY RESPONSE IN RHEUMATOID ARTHRITIS |
title_short |
AB0122 THE NORA PROJECT - PREDICTION OF THERAPY RESPONSE IN RHEUMATOID ARTHRITIS |
title_full |
AB0122 THE NORA PROJECT - PREDICTION OF THERAPY RESPONSE IN RHEUMATOID ARTHRITIS |
title_fullStr |
AB0122 THE NORA PROJECT - PREDICTION OF THERAPY RESPONSE IN RHEUMATOID ARTHRITIS |
title_full_unstemmed |
AB0122 THE NORA PROJECT - PREDICTION OF THERAPY RESPONSE IN RHEUMATOID ARTHRITIS |
title_sort |
ab0122 the nora project - prediction of therapy response in rheumatoid arthritis |
publisher |
BMJ |
publishDate |
2021 |
url |
http://dx.doi.org/10.1136/annrheumdis-2021-eular.2024 https://syndication.highwire.org/content/doi/10.1136/annrheumdis-2021-eular.2024 |
long_lat |
ENVELOPE(20.166,20.166,70.157,70.157) |
geographic |
Arctic Elia |
geographic_facet |
Arctic Elia |
genre |
Arctic |
genre_facet |
Arctic |
op_source |
Annals of the Rheumatic Diseases volume 80, issue Suppl 1, page 1090.2-1090 ISSN 0003-4967 1468-2060 |
op_doi |
https://doi.org/10.1136/annrheumdis-2021-eular.2024 |
container_title |
Annals of the Rheumatic Diseases |
container_volume |
80 |
container_issue |
Suppl 1 |
container_start_page |
1090.2 |
op_container_end_page |
1090 |
_version_ |
1790597049060687872 |